12:00 AM
 | 
Aug 03, 2015
 |  BC Week In Review  |  Company News  |  Deals

Intrexon, Oragenics deal

Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically modified Lactococcus lactis platform, including AG013, to treat oral mucositis (OM) and other diseases of the oral cavity, throat and esophagus. The deal excludes the use of the products for the prophylaxis of cancer.

Intrexon will undertake technology discovery, cell-engineering development...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >